Cargando…
Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study
The coronavirus disease 2019 (COVID-19) pandemic has placed a significant burden on hospitals worldwide. Objective biomarkers for early risk stratification and clinical management are still lacking. The aim of this work was to determine whether bioactive adrenomedullin can assist in the risk stratif...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069401/ https://www.ncbi.nlm.nih.gov/pubmed/33924637 http://dx.doi.org/10.3390/jcm10081667 |
_version_ | 1783683228501016576 |
---|---|
author | Simon, Tim-Philipp Stoppe, Christian Breuer, Thomas Stiehler, Lara Dreher, Michael Kersten, Alexander Kluge, Stefan Karakas, Mahir Zechendorf, Elisabeth Marx, Gernot Martin, Lukas |
author_facet | Simon, Tim-Philipp Stoppe, Christian Breuer, Thomas Stiehler, Lara Dreher, Michael Kersten, Alexander Kluge, Stefan Karakas, Mahir Zechendorf, Elisabeth Marx, Gernot Martin, Lukas |
author_sort | Simon, Tim-Philipp |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic has placed a significant burden on hospitals worldwide. Objective biomarkers for early risk stratification and clinical management are still lacking. The aim of this work was to determine whether bioactive adrenomedullin can assist in the risk stratification and clinical management of critically ill COVID-19 patients. Fifty-three patients with confirmed COVID-19 were included in this prospective observational cohort study between March and April 2020. Bioactive adrenomedullin (bio-ADM) plasma concentration was measured daily for seven days after admission. The prognostic value and clinical significance of bio-ADM plasma levels were evaluated for the severity of respiratory failure, the need for extracorporeal organ support and outcome (28-day mortality). Bio-ADM levels increased with the severity of acute respiratory distress syndrome (ARDS; p < 0.001) and were significantly elevated in invasively ventilated patients (p = 0.006) and patients in need of extracorporeal membrane oxygenation (p = 0.040) or renal replacement therapy (RRT; p < 0.001) compared to patients without these conditions. Non-survivors showed significantly higher bio-ADM levels than survivors (p = 0.010). Bio-ADM levels predicted 28-day mortality (C-index 0.72, 95% confidence interval 0.56–0.87, p < 0.001). Bio-ADM plasma levels correlate with disease severity, the need for extracorporeal organ assistance, and outcome, and highlight the promising value of bio-ADM in the early risk stratification and management of patients with COVID-19. |
format | Online Article Text |
id | pubmed-8069401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80694012021-04-26 Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study Simon, Tim-Philipp Stoppe, Christian Breuer, Thomas Stiehler, Lara Dreher, Michael Kersten, Alexander Kluge, Stefan Karakas, Mahir Zechendorf, Elisabeth Marx, Gernot Martin, Lukas J Clin Med Article The coronavirus disease 2019 (COVID-19) pandemic has placed a significant burden on hospitals worldwide. Objective biomarkers for early risk stratification and clinical management are still lacking. The aim of this work was to determine whether bioactive adrenomedullin can assist in the risk stratification and clinical management of critically ill COVID-19 patients. Fifty-three patients with confirmed COVID-19 were included in this prospective observational cohort study between March and April 2020. Bioactive adrenomedullin (bio-ADM) plasma concentration was measured daily for seven days after admission. The prognostic value and clinical significance of bio-ADM plasma levels were evaluated for the severity of respiratory failure, the need for extracorporeal organ support and outcome (28-day mortality). Bio-ADM levels increased with the severity of acute respiratory distress syndrome (ARDS; p < 0.001) and were significantly elevated in invasively ventilated patients (p = 0.006) and patients in need of extracorporeal membrane oxygenation (p = 0.040) or renal replacement therapy (RRT; p < 0.001) compared to patients without these conditions. Non-survivors showed significantly higher bio-ADM levels than survivors (p = 0.010). Bio-ADM levels predicted 28-day mortality (C-index 0.72, 95% confidence interval 0.56–0.87, p < 0.001). Bio-ADM plasma levels correlate with disease severity, the need for extracorporeal organ assistance, and outcome, and highlight the promising value of bio-ADM in the early risk stratification and management of patients with COVID-19. MDPI 2021-04-13 /pmc/articles/PMC8069401/ /pubmed/33924637 http://dx.doi.org/10.3390/jcm10081667 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Simon, Tim-Philipp Stoppe, Christian Breuer, Thomas Stiehler, Lara Dreher, Michael Kersten, Alexander Kluge, Stefan Karakas, Mahir Zechendorf, Elisabeth Marx, Gernot Martin, Lukas Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study |
title | Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study |
title_full | Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study |
title_fullStr | Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study |
title_full_unstemmed | Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study |
title_short | Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study |
title_sort | prognostic value of bioactive adrenomedullin in critically ill patients with covid-19 in germany: an observational cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069401/ https://www.ncbi.nlm.nih.gov/pubmed/33924637 http://dx.doi.org/10.3390/jcm10081667 |
work_keys_str_mv | AT simontimphilipp prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy AT stoppechristian prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy AT breuerthomas prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy AT stiehlerlara prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy AT drehermichael prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy AT kerstenalexander prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy AT klugestefan prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy AT karakasmahir prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy AT zechendorfelisabeth prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy AT marxgernot prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy AT martinlukas prognosticvalueofbioactiveadrenomedullinincriticallyillpatientswithcovid19ingermanyanobservationalcohortstudy |